Alkermes (ALKS) Expected to Announce Earnings on Thursday

Alkermes (NASDAQ:ALKS) is anticipated to release its Q3 2025 results before the market opens on Thursday, October 23rd. Analysts expect Alkermes to post earnings of $0.41 per share and revenue of $355.23 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:00 AM ET.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. The business had revenue of $390.66 million for the quarter, compared to analyst estimates of $343.20 million. Alkermes had a net margin of 23.15% and a return on equity of 24.86%. The business’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter last year, the business earned $1.16 earnings per share. On average, analysts expect Alkermes to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Price Performance

ALKS opened at $30.98 on Tuesday. The business has a 50 day moving average price of $29.22 and a two-hundred day moving average price of $29.10. The company has a market capitalization of $5.11 billion, a price-to-earnings ratio of 14.89, a price-to-earnings-growth ratio of 1.63 and a beta of 0.54. Alkermes has a 1-year low of $25.17 and a 1-year high of $36.45.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $31.53, for a total value of $283,770.00. Following the completion of the sale, the executive vice president owned 73,740 shares in the company, valued at $2,325,022.20. This represents a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alkermes

Large investors have recently made changes to their positions in the business. Osaic Holdings Inc. raised its position in Alkermes by 56.4% during the second quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock valued at $56,000 after acquiring an additional 701 shares in the last quarter. Public Sector Pension Investment Board boosted its stake in Alkermes by 8.8% in the 2nd quarter. Public Sector Pension Investment Board now owns 636,913 shares of the company’s stock valued at $18,222,000 after buying an additional 51,651 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Alkermes by 88.5% in the second quarter. Tower Research Capital LLC TRC now owns 13,710 shares of the company’s stock valued at $392,000 after acquiring an additional 6,437 shares during the last quarter. Corient Private Wealth LLC grew its holdings in Alkermes by 3.8% during the 2nd quarter. Corient Private Wealth LLC now owns 41,494 shares of the company’s stock worth $1,187,000 after acquiring an additional 1,519 shares during the last quarter. Finally, E Fund Management Co. Ltd. raised its position in shares of Alkermes by 28.0% during the second quarter. E Fund Management Co. Ltd. now owns 18,003 shares of the company’s stock worth $515,000 after acquiring an additional 3,943 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Analysts Set New Price Targets

ALKS has been the topic of a number of research analyst reports. The Goldman Sachs Group initiated coverage on Alkermes in a report on Tuesday, July 15th. They set a “buy” rating and a $43.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Alkermes in a research note on Tuesday, October 14th. JPMorgan Chase & Co. increased their target price on shares of Alkermes from $34.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, September 9th. HC Wainwright restated a “neutral” rating and issued a $46.00 price target on shares of Alkermes in a research report on Tuesday, September 9th. Finally, Needham & Company LLC set a $43.00 price target on Alkermes in a report on Tuesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.